In a significant breakthrough, an Indian pharmaceutical company has announced the development of the country’s first indigenous, room temperature stable drug for sickle cell disease, set to be available at a mere 1% of the global price. This groundbreaking achievement is poised to revolutionize the treatment landscape, with the company expected to offer the medicine to the government for less than ₹600.
Union Health Minister Mansukh Mandaviya has lauded this development, recognizing its potential to combat sickle cell disease and pave the way for a healthier India. Sickle cell disease, a genetic blood disorder that profoundly impacts patients’ lives, has long been a public health concern.
The newly developed room temperature stable oral suspension of Hydroxyurea is tailored to meet the specific needs of patients battling sickle cell disease across all age groups. Unlike the current imported hydroxyurea solution, which demands storage at 2-8 degrees Celsius and comes with a hefty price tag of approximately ₹77,000, this indigenous drug ensures affordability and accessibility.
The pharmaceutical company plans to provide oral syringes for precise dosage administration, further enhancing patient convenience and adherence to treatment. This milestone comes at a crucial time as India grapples with the disproportionate impact of sickle cell disease on tribal communities, with the Central government recently launching a mission to eliminate the disease by 2047.
With the introduction of this affordable indigenous drug, India takes a significant step towards fulfilling its commitment to healthcare equity and universal access to essential medications. This landmark achievement not only underscores the prowess of Indian pharmaceutical innovation but also heralds hope for millions of individuals affected by sickle cell disease across the nation.
